Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
about
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@en
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@nl
type
label
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@en
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@nl
prefLabel
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@en
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@nl
P2093
P2860
P1433
P1476
Safety and efficacy of a TTR s ...... yretin amyloid cardiomyopathy.
@en
P2093
Harvey Feigenbaum
Jessica Smith
Merrill D Benson
Noel R Dasgupta
P2860
P304
P356
10.1080/13506129.2017.1374946
P577
2017-09-14T00:00:00Z